Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid

Objective Oligomeric forms of amyloid β protein (oAβ) are believed to be principally responsible for neurotoxicity in Alzheimer disease (AD), but it is not known whether anti‐Aβ antibodies are capable of lowering oAβ levels in humans. Methods We developed an ultrasensitive immunoassay and used it to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of neurology 2019-08, Vol.86 (2), p.215-224
Hauptverfasser:	Yang, Ting, Dang, Yifan, Ostaszewski, Beth, Mengel, David, Steffen, Verena, Rabe, Christina, Bittner, Tobias, Walsh, Dominic M., Selkoe, Dennis J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Alzheimer Disease - cerebrospinal fluid Alzheimer Disease - drug therapy Alzheimer's disease Amyloid Amyloid beta-Peptides - antagonists & inhibitors Amyloid beta-Peptides - cerebrospinal fluid Antibodies Antibodies, Monoclonal, Humanized - administration & dosage Biomarkers Biomarkers - cerebrospinal fluid Cerebrospinal fluid Clinical trials Drug Delivery Systems - methods Female Humans Immunoassay Intravenous administration Male Middle Aged Neurodegenerative diseases Neurotoxicity Oligomers Pharmacodynamics Pharmacology Target recognition
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!